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Impact of hypertension on cardiomyopathy, morbidity and mortality in
end-stage renal disease. A cohort of 432 ESRD (261 hemodialysis and 171
peritoneal dialysis) patients was followed prospectively for an average of
41 months. Baseline and annual demographic, clinical and echocardio-
graphic assessments were performed, as well as serial clinical and labora-
tory tests measured monthly while on dialysis therapy. The average mean
arterial blood pressure level during dialysis therapy was 101 11 mm Hg.
After adjusting for age, diabetes and ischcmic heart disease, as well as
hemoglobin and serum albumin levels measured serially, each 10 mm Hg
rise in mean arterial blood pressure was independently associated with:
the presence of concentric LV hypertrophy (OR 1.48, P = 0.02), the
change in LV mass index (/3 = 5.4 g/m2,P 0.027) and cavity volume (/3 =
4.3mI/rn2, P = 0.048) on follow-up echocardiography, the development of
de novo cardiac failure (RR 1.44, P = 0.007), and the development of de
novo ischemic heart disease (RR 1.39, P = 0.05). The association with LV
dilation was of borderline statistical significance (OR 1.48, P = 0.06).
Mean arterial blood pressures greater than 106 mm Hg were associated
with both echocardiographic and clinical endpoints. Paradoxically, low
mean arterial blood pressure (RR 1.36 per 10 mm Hg fall, P = 0.009)was
independently associated with mortality. The association of low blood
pressure with mortality was a marker for having had cardiac failure prior
to death. We conclude that even moderate hypertension worsens the
echocardiographic and clinical outcome in ESRD patients, especially in
those without previous clinical cardiac disease.
Dialysis patients have an age-adjusted death rate estimated to
be 3.5 times that of the general population [1]. A considerable
proportion of this excess mortality can be explained by the high
baseline prevalence of non-renal comorbid conditions, such as
diabetes mellitus and cardiovascular disease, among patients
starting end-stage renal disease therapy [2—6]. In recent years,
there has been a growing realization that factors that are unre-
lated to baseline comorbid illnesses may be causes, or markers, of
poor outcome in dialysis patients. For example, it is generally
accepted that a low serum albumin concentration [7—101, probably
a reflection of malnutrition, and the amount of solute removal
during dialysis [8, 11—15] are independent predictors of mortality
in these patients.
Hypertension is very common among ESRD patients. It has
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long been believed that hypertension is a major cause of morbidity
and mortality in dialysis patients [14, 16—19}, as is the case in the
general population [20]. There is very little controlled evidence to
support this widely held belief. On the contrary, two very large
epidemiological studies have shown the opposite: low, not high,
blood pressure was associated with increased mortality rates in
ESRD patients [2, 21]. The blood pressure level that minimizes
death risk in dialysis patients has not been determined, largely
because there have been few if any long-term studies to gauge its
impact. In the absence of such studies, our current rationale for
the treatment of hypertension in ERSD patients has been extrap-
olated from the treatment of otherwise healthy essential hyper-
tensive patients in the general population.
We recently completed a prospective study of a cohort of 433
patients followed from the initiation of ESRD therapy for periods
of up to 10 years [22, 23]. In this paper we report on the impact of
blood pressure on echocardiographic abnormalities, cardiac mor-
bidity and mortality.
Methods
Patients
This prospective cohort study was started in the Royal Victoria
Hospital Montreal, Quebec in 1982, in the Health Sciences
Centre, St John's, Newfoundland in 1984, and in the Grace
Hospital, St. John's, Newfoundland in 1985. Patients were eligible
for entry to the study if (a) they survived for six months, and (b)
if they had a technically satisfactory echocardiogram within a year
of starting renal replacement therapy. Patient recruitment fin-
ished in June 1991. Of 518 patients who survived at least six
months from the start of ESRD therapy, a cohort of 433 (83.6%
of those eligible) entered the study. One study patient was treated
only with renal transplantation. Eighty-five patients were excluded
for the following reasons: failure to obtain a technically adequate
echocardiogram within one year of starting therapy (71 patients),
started therapy elsewhere (7 patients), charts mislaid (5 patients),
refusal to participate (2 patients).
The mean patient follow-up was 41 months. Patients were
divided into four groups of approximately similar size according to
the time period in which dialysis therapy was initiated: 1982 to
1984 (20.3%, mean follow-up on dialysis 38 32 months), 1985
to 1986 (17.3%, mean follow-up on dialysis 37 24 months), 1987
to 1988 (27.5%, mean follow-up on dialysis 27 19 months) and
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1989 to 1991 (34.9%, mean follow-up on dialysis 18 10 months).
There were no differences in mean arterial blood pressure levels
(103 9, 101 10, 101 12 and 101 11 mm Hg, respectively,
P = 0.42) or the number of antihypertensive medications (1.1
1.2, 1.2 1.2, 1.0 1.0, respectively, P = 0.23) according to time
period of entry into the study. There was no relationship between
the average mean arterial blood pressure level and the time spent
on dialysis therapy: the mean arterial blood pressure was 101 12
mm Hg in those who spent 1 year on dialysis (N = 104), 102
11 mm Hg in those who spent ito  2 years on dialysis (N 127),
100 9 mm Hg in those who spent 2 to  3 years on dialysis (N =
75), 101 Ii mm Hg in those who spent 3 to  4 years on dialysis
(N = 44), and 101 10 mm Hg in those who spent> 4 years on
dialysis (N = 75, P = 0.94). These data suggest that (a) mean
arterial blood pressure level is not a surrogate measure for the era
when ESRD therapy was initiated and (b) that mean arterial
blood pressure levels were not time-dependent.
Data collection
At baseline, and at yearly intervals thereafter, a clinical assess-
ment was undertaken to detect the presence of cardiovascular
disease. At monthly intervals the data collected included blood
pressure, hemoglobin and serum albumin levels and interdialytic
weight gain. Blood pressure and blood tests were carried out
immediately prior to dialysis in hemodialysis patients by dialysis
nursing staff. Blood pressure was measured in the contralateral
arm in patients with patent arteriovenous fistulae or grafts. For
each subject hemoglobin, serum albumin, systolic blood pressure
and diastolic blood pressure levels were reported as the mean of
the monthly values while on dialysis therapy. At yearly intervals all
changes related to renal replacement therapy, blood transfusions,
use of recombinant human erythropoietin, antihypertensive and
cardiac medication use, admissions to hospital and autopsy notes
were recorded. Baseline and annual echocardiography were per-
formed using M-mode and two-dimensional ultrasonography.
Left ventricular mass index was calculated according to the Penn
convention [24]. Left ventricular cavity volume was calculated by
the formula of Pombo, Troy and Russell [25]. The initial echo-
cardiogram was performed within (mean SD) 3 4 (median 0.5)
months from the start of ESRD therapy. A total of 298 patients
remained alive or untransplanted in the study at one year, and 275
patients had a repeat echocardiogram at an interval of 16 10
(median 13) months following the initial study. This patient subset
was almost identical to the parent group of 433 patients, with no
statistically significant differences in terms of baseline clinical and
echocardiographic parameters.
Clinical events, such as cardiac failure and ischemic heart
disease were derived from dialysis records, and admission and
discharge summaries collected by the research nurse. The rating
of clinical events was performed by a single nephrologist, blinded
to other data points, based on discharge summaries, radiologic,
electrocardiographic and laboratory reports during the admission.
Echocardiograms were performed and read at the local centres
using the criteria of the American College of Echocardiography.
The vast majority of procedures were done as part of the research
protocol. In the few cases where more than one echocardiogram
was performed within a given year, data were abstracted from that
nearest to one calendar year from the baseline echocardiogram.
The echocardiographers were blinded to clinical data points. In
particular, they had no knowledge of mean arterial blood pres-
sure, serum albumin and hemoglobin levels. We have previously
reported a very high degree on inter-rater reliability of echocar-
diograms performed on our ESRD patients [26].
Definitions
The following definitions were used. Mean arterial blood
pressure was calculated as diastolic blood pressure + 1/3(systolic
blood pressure — diastolic blood pressure). Coronary artery
disease was defined as a previous history of myocardial infarction,
coronary artery bypass surgery or percutaneous transluminal
angioplasty. Angina pectoris was defined as precordial chest pain,
precipitated by exertion or stress, which could be relieved by rest
or nitrate therapy. Ischemic heart disease was coronary artery
disease or angina pectoris.
Cardiac failure was defined as dyspnea plus two of the follow-
ing: raised jugular venous pressure, bibasalar crackles, pulmonary
venous hypertension or interstitial edema on chest X-ray, requir-
ing hospitalization or extra ultrafiltration. There is no easily
applied method to differentiate cardiac failure resulting simply
from fluid overload from that due to myocardial dysfunction. We
have previously reported that patients who exhibit these charac-
teristics at baseline have a very poor prognosis, even without
accurate knowledge of the state of their myocardiums at the time
of the event, and that only 11% of patients who had cardiac failure
had a normal echocardiogram [23]. It is likely, therefore, that
clinical cardiac failure is very often indicative of underlying
cardiac disease.
De novo cardiac failure was admission for cardiac failure while
on dialysis therapy in a patient without a history of cardiac failure
at baseline. Recurrent cardiac failure was admission for cardiac
failure while on dialysis therapy in a patient with a history of
cardiac failure at baseline. De novo ischemic heart disease was
defined as admission for ischemic heart disease while on dialysis
therapy in a patient without a history of ischemic heart disease at
baseline. Recurrent ischemic heart disease was admission for
ischemic heart disease while on dialysis therapy in a patient with
a history of ischemic heart disease at baseline.
Echocardiographic systolic dysfunction was fractional shorten-
ing  25%. LV dilation was defined as LV cavity volume > 90
mum2 [25], with no systolic dysfunction. LV hypertrophy was LV
mass index > 131 g/m2 in males, > 100 g/m2 in females [27].
Concentric LV hypertrophy was LV hypertrophy with normal
cavity volume [28], no systolic dysfunction. Normal LV was
absence of hypertrophy, dilation and systolic dysfunction. Pre-
dominant mode of dialysis therapy was defined as > 50% of total
dialysis time on a particular mode of dialysis (peritoneal dialysis
or hemodialysis).
Analysis
For clinical events, hemoglobin, mean arterial blood pressure
and serum albumin levels were averaged from the monthly values,
from the beginning of dialysis therapy up to the development of
the event in question. Take, for example a patient who develops
de novo ischemic heart disease after 10 months, de novo cardiac
failure after 30 months and dies after 40 months on dialysis. In the
analysis of (a) time to death, the blood pressure used would be the
average of all 40 monthly readings; (b) time to ischemic heart
disease, the blood pressure used would be the average of the first
10 monthly readings; (c) time from admission for ischemic heart
disease to death, the blood pressure used would be the average of
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I II
Baseline data
Age years 51.1 16.7 54.2 15.1
Male/female % 64.4/35.6 62.9/37.1
Diabetes mellitus % 26.8 26.3
Renal disease %
Glomerulonephritis 30.9 29.5
Diabetic nephropathy 19.9 18.0
Tubulointerstitial 11.1 11.5
Genetic 7.4 7.9
Nephrosclerosis 6.5 7,6
Other 17.6 18.7
Unknown 6.7 6.8
Hypertension > 10 years % 29.1 32.4
Ischemic heart disease % 21.9 25.2
Cardiac failure % 30.8 33.1
Serial data
MAP mmHg 101±11 101±11
Serum albumin g/dl 3.7 0.5 3.7 0.4
Hemoglobin g/dl 9.0 1.6 8.9 1.5
the last 30 monthly readings; (d) time to cardiac failure, the blood
pressure used would be the average of the first 30 monthly
readings; and for (e) time to death following admission for cardiac
failure, the blood pressure used would be the average of the last
10 monthly readings. Hemoglobin and serum albumin levels were
handled similarly. For echocardiographic outcomes, hemoglobin,
mean arterial blood pressure and serum albumin levels were
averaged from the monthly values, from the first to the second
echocardiogram. Where subjects had more than one follow-up
echocardiogram, the first follow-up echocardiogram was chosen
for the analyses presented here. For each outcome reported here,
the impact of mean arterial blood pressure level was adjusted for
age, diabetes mellitus, ischemic heart disease, mean serum albu-
min, and mean hemoglobin level. For the analyses of time to
development of ischemic heart disease, time to development of
cardiac failure and time to death, patients were censored at the
time of renal transplantation or at final follow-up. Normally
distributed continuous variables were compared using t-tests or
analysis of variance. Categorical variables were compared using
chi-squared analysis. Multiple logistic regression was used to
assess the association of blood pressure with echocardiographic
diagnosis on repeat echocardiography. Multiple linear regression
was used to assess the impact of blood pressure on the differences
in left ventricular mass index, cavity volume index and fractional
shortening between the first and second echocardiograms. The
independent impact of blood pressure on death rates, and the
rates of cardiac failure and ischemic heart disease were assessed
using Cox's proportional hazards modelling. All statistical tests
are two-tailed with a P-value less than 0.05 taken to indicate
statistical significance. All multivariate analyses incorporated a
stepping procedure, and were performed using BMDP software
[291.
mm Hg
P for
98 98—106 > 106 trend
Baseline data
Age years 55.8 16.3 50.0 16.6 48.0 16.2 0.002
Male/female % 61 .0/39.0 61.7/38.3 71.3/28.7 0.134
Diabetes mellitus % 32.6 23.2 21.3 0.103
Hypertension 36.9 48.5 19.1 0.007
> 10 years
Ischemic heart 32.6 20.8 13.2 0.0005
disease %
Cardiac failure % 40.4 30.4 22.8 0.006
Serial data
Hemoblobin g/dl 8.7 1.4 8.9 1.5 8.9 1.6 0.459
Serum albumin g/dl 3.6 0.5 3.7 0.5 3.8 0.4 0.030
are expressed as mean plus or minus standard
Results
Patient characteristics
The clinical and demographic characteristics of the patient
cohort, at the time of patient entry, are shown in Table 1. The
cohort was almost entirely Caucasian. Hemodialysis and perito-
neal dialysis were the predominant mode of dialysis therapy in
60.5% and 39.5% of subjects, respectively. Comparing hemodial-
ysis to peritoneal dialysis patients, differences in mean hemoglo-
bin (8.4 1.4 vs. 9.6 1.5 g/liter, P < 0.0001) and serum albumin
(3.9 0.4 vs. 3.5 0.5 g/liter, P < 0.0001) were seen, while mean
arterial blood pressure levels were similar (101.7 10.6 vs. 100.8
11.0mm Hg, P = 0.352). On average patients received 1.2 2.1
(10th percentile was zero; median 0.9; 90th precentile, 3.0)
different antihypertensive medications while on dialysis therapy.
Calcium channel blockers (3,147 patient months) were the most
frequently used antihypertensive medication, followed by beta-
blockers (2,707 patient months), ACE-inhibitors (1,546 patient
months), vasodilators (1,457 patient months) and centrally acting
agents (520 patient months).
One third of patients had an average mean arterial blood
pressure less than 98 mm Hg (mean SD 90 7 mm Hg), one
third between 98 and 106 mm Hg (102 2 mm Hg), and one third
had levels greater than 106 mm Hg (113 5 mm Hg). The
characteristics of patients in the different tertiles of mean arterial
blood pressure are shown in Table 2. Patients with lower mean
arterial blood pressure levels while on dialysis therapy had
adverse prognostic features at baseline: older age (P = 0.002),
hypoalbuminemia (P 0.03), ischemic heart disease (P = 0.0005)
and cardiac failure (P = 0.006).
Outcomes
Of our patients, 259 had evaluable serial echocardiograms
(Table 3). Only 35 had normal left ventricles on follow-up.
Concentric hypertrophy was present in 39.4%, LV dilation in
25.1% and systolic dysfunction in 22%. The mean change (second
minus first) in left ventricular mass was 3.4 47.1 g/m2 (range
—133 to +138 g/m2). For cavity volume the mean difference was
3.0 40.1 ml/m2 (range —225 to +142 ml/m2). Fractional
shortening rose on average by 1.0 8.4% (range —20 to +24%).
Table 1. Patient characteristics for all patients (group I, N = 432) and
patient subset with repeat echocardiograms (group II, N = 278)
Table 2. Patient characteristics according to tertile of mean arterial
blood pressure level
Continuous variables
deviation.
MAP denotes mean arterial blood pressure. There were no statistically
significant differences between group I and group II.
a Continuous variables are expressed as mean plus or minus standard
deviation
1382 Foley et al: Hypertension and cardiomyopathy in ESRD
Outcome
#Events/#
at risk (%)
MAP
mm Hg P
Diagnosis on repeat
echocardiogram
Normal (reference categoly) 35/259 (13.5%) 99 15 —
Concentric LV hypertrophy 102/259 (39.4%) 104 10 0.02
LV dilation 65/259 (25.1%) 103 11 0.08
Systolic dysfunction 57/259 (22.0%) 97 12 0.73
Cardiac failure
De novo
No 227/299 (75.9%) 102 11 —
Yes 72/299 (24.1%) 104 9 0.27
Recurrent
No 62/133 (46.6%) 101 9 —
Yes 71/133 (53.4%) 101 12 0.84
Death following admission
No 47/133 (35.3%) 104 11 —
Yes 86/133 (64.7%) 95 13 0.0001
Ischemic heart disease
De novo
No 297/337 (88.1%) 103 11 —
Yes 40/337 (11.9%) 103 10 0.58
Recurrent
No 49/95 (51.6%) 98 10 —
Yes 46/95 (48.4%) 101 11 0.18
Death following admission
No 23/73 (31.5%) 101 10 —
Yes 50/73 (68.5%) 95 13 0.10
Death
No 282/432 (65.3%) 103 10 —
Yes 150/432 (34.7%) 98 8 <0.0001
Ignoring sign, the absolute difference in LV mass was 47.2 42.6
g/m2, representing an increase in mass in 69.8%, and a decrease in
mass in 30.2%. The absolute change in cavity volume was 24.5
22.3 mi/rn2 (increased in 50.2%, decreased in 49.8%). The abso-
lute change in fractional shortening was 6.5 5.4% (increased in
41.6%, decreased in 58.4%).
A total of 143 of 432 (33%) patients developed cardiac failure
during the study, of which 50.3% were de novo episodes. A total
of 86 patients were admitted because of ischemic heart disease, of
which 44% were de novo episodes. The overall median survival
time for the patient cohort was 50 months. The 150 deaths
observed were attributed to myocardial infarction in 10%, sudden
death in 26%, other cardiac causes in 11%, other vascular disease
in 11%, infection in 14%, treatment withdrawal in 12.1% and to
other causes in 15.4%.
Prognostic impact of mean arterial blood pressure
Total group. On univariate analysis (Table 3) higher blood
pressuer levels were associated with the presence of concentric
LV hypertrophy on repeat echocardiography (P = 0.02), while
lower blood pressure levels were associated with death following
admission for cardiac failure (P = 0.0001) and overall mortality
(P < 0.0001).
In logistic regression models (Table 4), in which patients with
normal left ventricles were used as reference group, each 10 mm
Hg rise in average mean arterial blood pressure level was associ-
ated with a 48% increased likelihood of having both concentric
Normal LV (reference category)
Concentric left ventricular hypertrophy
Left ventricular dilation
Systolic dysfunction
Change in left ventricular
Mass index g/rn2
Cavity volume mi/rn2
Fractional shortening %
Ischemic heart disease
De novo
Recurrent
Cardiac failure
De novo
Recurrent
Death
13(P)
Relative risk (P)
The covariates entered in each multivariate analysis were age, diabetes
mellitus, ischemic heart disease (excluded for the outcomes de novo and
recurrent ischemic heart disease) and the average monthly mean arterial
blood pressure, serum albumin and hemoglobin level before the index
event.
LV hypertrophy and LV dilation on second echocardiogram.
Blood pressure level had no independent association with systolic
dysfunction on second echocardiogram. In multiple linear regres-
sion models, mean arterial blood pressure was independently
associated with an increase in mass index (13 = 5.4 g/m per 10 mm
Hg) and cavity volume (/3 = 4.3 ml/m2 per 10 mm Hg) from first
to second echocardiogram, but had no association with the change
in fractional shortening.
Using Cox's regression modelling, each 10 mm Hg rise in mean
arterial blood pressure level while on dialysis therapy was inde-
pendently associated with the development of de novo cardiac
failure (RR 1.44), and de novo ischemic heart disease (RR 1.39).
Mean arterial blood pressure level had no association with
recurrent cardiac failure or recurrent ischemic heart disease.
Adding baseline smoking status, electrocardiographic ST-segment
abnormalities and serum cholesterol level to the multivarate
models had no impact on the association between blood pressure
and ischemic heart disease.
Paradoxically, given the direct association of mean arterial
blood pressure with ischemic heart disease and cardiac failure,
mean arterial was inversely associated with mortality. Thus, low,
not high, blood pressure was associated with earlier death inde-
pendently of age, diabetes, ischemic heart disease, anemia and
hypoalbuminemia. Cardiac failure, a highly lethal condition that
preceded 65% of all deaths in this study, confounded the true
impact of hypertension. In these patients, the median time to
development of cardiac failure was 13 months. The median
survival following the development of cardiac failure was 20
months. Mean arterial blood pressure in these patients fell from
103 10 to 98 13 mm Hg (P < 0.0001) following the
development of cardiac failure. In a Cox model using age,
diabetes, ischemic heart disease and hemoglobin, albumin and
Table 3. Echocardiographic and clinical outcomes: Associated mean
arterial blood pressure levels
Table 4. Independent association between blood pressure (the effect of
a rise in mean arterial blood pressure level of 10 mm Hg) and
echocardiographic and clinical outcomes in the combined
group of hemodialysis and peritoneal dialysis patients
Outcome
Odds ratio (P)
1.48 (0.020)
1.48 (0.063)
no association
5.4 (0.027)
4.3 (0.048)
no association
1.39 (0.051)
no association
1.44 (0.007)
no association
0.82 (0.009)
Continuous variables are expressed as mean plus or minus standard
deviation. MAP denotes mean arterial blood pressure.
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Peritoneal
Hemodialysis dialysis
mean arterial blood pressure levels following the development of
cardiac failure, low mean arterial blood pressure was the strongest
predictor of mortality after the development of cardiac failure
(RR 1.43 per 10 mm Hg fall, P < 0.001). Mean arterial blood
pressure fell from 103 11 to 97 13 mm Hg, P < 0.0001)
following admission for ischemic heart disease. Mean arterial
blood pressure following admission for ischemic heart disease had
no independent association with subsequent mortality.
The 90th percentile for mean arterial blood pressure was 114
mm Hg. The analyses shown in Table 4 were repeated with
patients whose blood pressure exceeded 114 mm Hg excluded. In
these models high mean arterial blood pressure was indepen-
dently associated with concentric LV hypertrophy (OR 1.63, P =
0.015), change in mass index (13 6.9 g/m2, P = 0.015) and de novo
cardiac failure (RR 1.72, P = 0.005) but no longer associated with
LV dilation, change in cavity volume or de novo ischemic heart
disease. Patients were divided according to the tertile of mean
arterial blood pressure level while on dialysis. The outcomes used
and adjustment eovariates were similar to those shown in Table 4.
Compared to subjects whose mean arterial blood pressure was
98 mm Hg, those with levels between 98 and 106 mm Hg were
more likely to have concentric LV hypertrophy on follow-up
echocardiography (adjusted OR 3.07, P = 0.025), while those with
levels greater than 106 mm Hg tended to have more concentric
LV hypertrophy (adjusted OR 2,33, P = 0.07) and were more
likely to be admitted for new-onset cardiac failure (adjusted RR
2.96, P = 0.002).
Hemodialysis patients. In hemodialysis patients, each 10 mm Hg
rise in mean arterial blood pressure level was associated with an
increased LV mass index on follow-up echocardiography (13 7.2
g/m2, P = 0.048), an increased likelihood of developing cardiac
Discussion
In this study we found that high blood pressure during dialysis
therapy was associated with several adverse outcomes, including
concentric LV hypertrophy, LV dilation, ischemic heart disease
and cardiac failure. In spite of the adverse impact of high blood
pressure on these events, we found an inverse association between
average blood pressure level while on dialysis and mortality. The
association between blood pressure level and the clinical and
echocardiographic outcomes was independent of other factors
thought to impact on ESRD patient outcome, namely age,
diabetes mellitus, ischemic heart disease, hemoglobin level and
serum albumin levels measured during dialysis therapy [2, 4,
5—101. The impact of hypertension was different in peritoneal and
hemodialysis patients, which may have been a consequence of the
reduction in patient numbers necessitated by subgroup analysis.
The data presented here suggest that uncontrolled blood pressure
leads to cardiomyopathy, and subsequently cardiac failure, a
highly lethal condition in this patient cohort [231. Following the
development of cardiac failure, low blood pressure predicts
mortality, and is likely to be a marker for the severity of cardiac
disease.
Cardiomyopathy
It is well known that high blood pressure is associated with left
ventricular hypertrophy in the general population. According to
the Law of Laplace (Tension = Pressure x Radius/2 X Wall
Thickness) wall tension, in the face of pressure overload, is
maintained constant by proliferation of sarcomeres in parallel
with existing sarcomeres, leading to wall thickening. High blood
pressure levels have also been associated with left ventricular
hypertrophy in ESRD patients [22, 30, 31]. In this study a high
mean arterial blood pressure following the initiation of dialysis
was associated with both left ventricular hypertrophy and left
ventricular dilatation on repeat echocardiography. In addition,
high blood pressure was also independently associated with the
change in mass index and cavity volume seen between the baseline
and follow-up echocardiograms. Even modest blood pressure
elevations, not even to currently defined hypertensive levels, were
Table 5. Independent association between blood pressure (the effect of
a rise in mean arterial blood pressure level of 10 mm Hg) and
echocardiographic and clinical outcomes analyzed separately
for hemodialysis and peritoneal dialysis patients
Outcome
Normal LV (reference category)
Concentric left ventricular
hypertrophy
Left ventricular dilation
Systolic dysfunction
Change in left ventricular
Mass index g/m2
Cavity volume mi/rn2
Fractional shortening %
Ischemic heart disease
De novo
Recurrent
Cardiac failure
Dc novo
Recurrent
Death
failure for the first time while while on dialysis therapy (RR 2.07,
P = 0.004) (Table 5). An inverse relationship between blood
pressure and mortality was observed (RR 1.37 per 10 mm Hg fall
in mean arterial blood pressure, P = 0.004). Mean arterial blood
pressure level had no independent association with concentric
hypertrophy, LV dilation, systolic dysfunction on follow-up echo-
Odds ratio (F) Odds ratio (P) cardiogram, changes in cavity volume or fractional shortening,
— — recurrent cardiac failure or de novo or recurrent ischemic heart
no association 2.16 (0.018) disease in hemodialysis patients. Adding interdialytic weight gain
no association no association as a covariate had no impact on the changes observed in the
no association no association echocardiographic parameters, or the clinical outcomes.
13 (F) (P) Peritoneal dialysis patients. Hypertension was associated with
concentric left ventricular hypertrophy on follow-up echocardiog-
7.2 (0.048) no association raphy (OR 2.16 per 10 mm Hg rise, P 0.018) and de novo
no association rio association ischemic heart disease (RR 1.95 per 10 mm Hg, P = 0.037) in
no association no association peritoneal dialysis patients (Table 5). Mean arterial blood pres-
Relative risk (P) Relative risk (P) sure level had no association with LV dilation, systolic dysfunction
or the changes seen in mass index, cavity volume or fractional
no association 1.95 (0.037) .
no association no association shortening, de novo cardiac failure, de novo or recurrent cardiac
failure, recurrent ischemic heart disease or death in the subgroup
treated with peritoneal dialysis.2.07 (0.004)
no association
0.73 (0.004)
no association
no association
no association
The covariates entered in each multivariate analysis were age, diabetes
mellitus, ischemic heart disease (excluded for the outcomes de novo and
recurrent ischemic heart disease) and the average monthly mean arterial
blood pressure, serum albumin and hemoglobin level before the index
event.
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associated with wall thickening and concentric left ventricular
hypertrophy. For purposes of illustration, a blood pressure of
140/90 mm Hg is equivalent to a mean arterial blood pressure of
106.7 mm Hg. Mean arterial blood pressure levels below this level,
from 98 to 106 mm Hg were associated with increased LV mass
index, and the presence of concentric LV hypertrophy. A number
of studies have suggested that LV hypertrophy and/or dilation
worsen prognosis, both in ESRD [22, 32] and non-ESRD popu-
lations [33]. A recent study demonstrated that control of blood
pressure in hypertensive hemodialysis patients led to substantial
regression of left ventricular hypertrophy [34].
Ischemic heart disease
Rising blood pressure in this study was independently associ-
ated with the development of de novo ischemic heart disease.
Ischemic heart disease in this study, as in the Framingham study
[35], was defined clinically. It is known that ischemic heart disease
in ESRD patients is unassociated with coronary artery stenosis in
up to one quarter of patients [36]. It is also known that coronary
artery disease in ESRD patients can be silent [36], especially in
diabetics [37]. It was not feasible to do routine coronary arteriog-
raphy in this epidemiological study to determine the relative
importance of atherosclerotic and non-atherosclerotic disease. It
was not possible in this study to identify threshold levels of mean
arterial blood pressure independently associated with the devel-
opment of ischemic heart disease.
Cardiac failure
Cardiac failure was a very common and very lethal occurrence
in this study. It is likely that cardiomyopathy and ischemic disease
are major contributors to its occurrence [23]. In this study mean
arterial blood pressures greater than 106 mm Hg were indepen-
dently associated with the development of de novo cardiac failure.
Mortality
In this study there was an inverse relationship between average
blood pressure and mortality. Other large studies of ESRD
patients have also shown this unexpected relationship [2, 21] and
have shown a dose-response relationship [21]. Cardiac failure was
by far the predominant condition leading ultimately to death.
Following the onset of cardiac failure, the major predictor of
death was relative hypotension. The data presented here suggest
that the inverse relationship between blood pressure, averaged
from the start of ESRD until death, and mortality reflect the fact
that cardiac failure has occurred prior to death.
Blood pressure targets
The data presented suggest that blood pressure targets may
differ before and after cardiac failure. In the former case, very
tight blood pressure control, with mean arterial blood pressure
levels below 98 mm Hg minimized the occurrence and progression
of left ventricular hypertrophy. Blood pressure levels below 106
mm Hg, very close to a blood pressure of 140/90 mm Hg
minimized the occurence of cardiac failure. The appropriate
target blood pressure for ESRD patients once they develop
cardiac failure is unclear from this study.
Study limitations
This study started in 1982, long before quantification of dialysis
techniques had reached their current level of sophistication. As
such, the importance of factors such as adequacy of dialysis, blood
volume expansion, fistula flow rates and nutritional intake were
not formally assessed. Some of the end-points studied, such as
ischemic heart disease, and cardiac failure are defined on a
clinical basis. This is unavoidable in a large scale epidemiological
study like this one. For example, cardiac failure was diagnosed
without formal assessment of myocardial structure and function; it
is possible that some of the cases labeled as cardiac failure may
have been due purely to fluid overload in patients with normal
cardiac function. However, only 11% of patients who had cardiac
failure on initiation of dialysis had normal echocardiograms, and
patients with high interdialytic weight gains were not more likely
to be admitted for cardiac failure [23]. In view of the extremely
poor prognosis of patients who develop cardiac failure, whether or
not it is due to fluid overload, our clinical definition clearly
identifies a very high risk, though heterogeneous, patient subset.
It must is recognized that correlation does not imply causation.
Formal randomized controlled clinical trials will be required to
define the impact of hypertension treatment on cardiac morbidity
and mortality, and to define the optimal target blood pressure in
different subsets of ESRD patients.
Conclusions
Hypertension a major cause of cardiomyopathy and cardiac
morbidity in ESRD patients. On the contrary, relative hypoten-
sion is a potent marker of mortality in ESRD patients, probably
reflective of antemortem cardiac failure.
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